Tolerability and safety of GS-101 eye drops, an antisense oligonucleotide to insulin receptor substrate-1: A 'first in man' Phase i investigation

British Journal of Clinical Pharmacology

Volumn 68, Issue 2, 2009, Pages 169-173

  Kain, Hermann ^a   Goldblum, David ^a   Geudelin, Bernard ^b   Thorin, Eric ^c,d   Beglinger, Christoph ^d  

^a UNIVERSITY EYE CLINIC   (Switzerland)

^b Mediante GmbH   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Antiangiogenic; Cornea; Insulin receptor substrate 1; Pathologic neovascularization

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; EYE DROPS; GS 101; INSULIN RECEPTOR SUBSTRATE 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING TEST; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMMON COLD; CORNEA; CORNEA TRANSPLANTATION; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; GRAFT REJECTION; HEADACHE; HUMAN; INTRAOCULAR PRESSURE; LABORATORY TEST; MALE; MYALGIA; NEOVASCULAR GLAUCOMA; NEOVASCULARIZATION (PATHOLOGY); NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PRURITUS; RETROLENTAL FIBROPLASIA; RISK ASSESSMENT; SCREENING; SEROLOGY; SIDE EFFECT; SLIT LAMP; URINALYSIS;

ADULT; ANGIOGENESIS INHIBITORS; CORNEAL NEOVASCULARIZATION; DRUG ADMINISTRATION SCHEDULE; EYE; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; MALE; OLIGONUCLEOTIDES, ANTISENSE; OPHTHALMIC SOLUTIONS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68449088889     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03450.x     Document Type: Article

References (20)

1. Campochiaro PA. Retinal and choroidal neovascularization. J Cell Physiol 2000 184 : 301 10.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995 1 : 27 31.
3. Neumann E, Frithz A. Capillaropathy and capillaroneogenesis in the pathogenesis of rosacea. Int J Dermatol 1998 37 : 263 6.
4. Risau W. Mechanisms of angiogenesis. Nature 1997 386 : 671 4.
5. Liang L, Zhou T, Jiang J, Pierce JH, Gustafson TA, Frank SJ. Insulin receptor substrate-1 enhances growth hormone-induced proliferation. Endocrinology 1999 140 : 1972 83.
6. Senthil D, Ghosh Choudhury G, Bhandari BK, Kasinath BS. The type 2 vascular endothelial growth factor receptor recruits insulin receptor substrate-1 in its signalling pathway. Biochem J 2002 368 : 49 56.
7. Shaw LM. Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion. Mol Cell Biol 2001 21 : 5082 93.
8. Vuori K, Ruoslahti E. Association of insulin receptor substrate-1 with integrins. Science 1994 266 : 1576 8.
9. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 2002 283 : E413 22.
10. Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 2004 24 : 435 44.
11. Miele C, Rochford JJ, Filippa N, Giorgetti-Peraldi S, Van Obberghen E. Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. J Biol Chem 2000 275 : 21695 702.
12. White MF. The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Recent Prog Horm Res 1998 53 : 119 38.
13. Jiang ZY, He Z, King BL, Kuroki T, Opland DM, Suzuma K, Suzuma I, Ueki K, Kulkarni RN, Kahn CR, King GL. Characterization of multiple signaling pathways of insulin in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis. J Biol Chem 2003 278 : 31964 71.
14. Cursiefen C, Chen L, Dana MR, Streilein JW. Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea 2003 22 : 273 81.
15. Cursiefen C, Rummelt C, Kuchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea 2000 19 : 526 33.
16. Dadgostar H, Waheed N. The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. Eye 2008 22 : 761 7.
17. Al-Mahmood S, Colin S, Farhat N, Thorin E, Steverlynck C, Chemtob S. Potent in vivo anti-angiogenic effects of GS-101, an antisense oligonucleotide preventing the expression of insulin receptor substrate-1. J Pharmacol Exp Ther 2009 329 : 496 504.
18. Andrieu-Soler C, Berdugo M, Doat M, Courtois Y, BenEzra D, Behar-Cohen F. Downregulation of IRS-1 expression causes inhibition of corneal angiogenesis. Invest Ophthalmol Vis Sci 2005 46 : 4072 8.
19. Yu RZ, Baker B, Chappell A, Geary RS, Cheung E, Levin AA. Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem 2002 304 : 19 25.
20. Cursiefen C, Bock F, Kruse FE, Borderie V, Wilhelm F, Schirra F, Seitz B, Meller D, Frueh Epstein B, Thiel M. GS-101 eye drops, an antisense oligonucleotide against IRS-1, inhibit and regress corneal neovascularization: interim results of a multicentre double-blind randomized phase II clinical study. Ophthalmology 2009 in press).